Evaluation of Risk Factors for Arteriovenous Fistula Failure by Peripheral Venous Transcriptome Analysis

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/bfcc5533b50dc6a624c57b05838d0802.pdf

Abstract Title *

Evaluation of Risk Factors for Arteriovenous Fistula Failure by Peripheral Venous Transcriptome Analysis

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Tetsu Miyamoto tetsum@med.uoeh-u.ac.jp University of Occupational and Environmental Health The Second Department of Internal Medicine Fukuoka Japan *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

While arteriovenous fistula (AVF) is favored for hemodialysis patients due to its association with fewer complications, its primary patency rate remains unsatisfactory. Diabetes mellitus and hypertension have been reported as risk factors for AVF failure. However, the molecular mechanisms underlying venous remodeling in arterio-venous fistula for hemodialysis patients remain unclear. We conducted transcriptome analysis of veins collected during AVF creation to assess the risk of shunt failure.

Methods

To identify differentially expressed genes (DEGs) in venous tissues from patients who required vascular access intervention therapy (VAIVT) within one year after AVF creation.

Results

No significant differences were observed in the prevalence of hypertension or diabetes. A total of 282 DEGs were identified in this study. Enrichment analysis revealed altered expression of inflammation-related genes regulated by STAT2. Network analysis revealed S100A8, S100A9, and CXCR1 as hub genes.

Conclusion

Inflammation-related genes regulated by STAT2, expressed in anastomosed veins, may contribute to AVF stenosis and fistula failure.

Kewords